37 results about "Malignant Solid Neoplasm" patented technology

The invention relates to treatment on human malignant solid tumor by HNF4 alpha inducement and differentiation, in particularly to a method for utilizing Hepatocyte Neclear Factor-4 alpha (HNF4 alpha) to induce the differentiation of the human malignant solid tumor so as to be applied to the treatment on the malignant solid tumor and application thereof. The research shows that the modulation of gene expression of the HNF4 alpha of malignant solid tumor cells can effectively produce functions of the inducement and the differentiation on the tumor cells so as to provide a new treatment means for inducing and differentiating the tumor.

The invention provides construction and application of a fourth-generation chimeric antigen receptor T (CAR-T) cell (expressing IL-7 and CCL19) specific to Nectin-4 dual targets on the surface of a malignant tumor. Two spatial epitopes of a Nectin-4 antigen are taken as target points, and the constructed fourth-generation CAR-T is used for treating and expressing a malignant solid tumor of the Nectin-4 antigen to solve the immune escape problem of the CAR-T during treatment of the solid tumor; and the constructed fourth-generation CAR-T can enhance proliferative capacity and sustained survivability, so that the solid tumor is effectively treated, and a new strategy is provided for effective prevention and treatment of postoperative recurrence / metastasis of the solid tumor.

An application of the tumor cell nucleus monoantibody as the synergist in physically treating solid tumor by directionally combining with the necrotic tissue of tumor specifically and killing the tumor cells by the nuclein carried by it is disclosed. It features that the normal tissue can not be damaged.

The invention relates to a method for treating human malignant solid tumors by using hepatocyte nuclear factor-1alpha (HNF1alpha). Specifically, the invention relates to a method for inducing differentiation of human malignant solid tumor cells by using HNF1alpha, thereby treating malignant solid tumors. The study of the invention shows that tumor cells can be effectively induced to differentiate through regulation of the gene expression of malignant solid tumor cell HNF1alpha, thus providing a new means for induced differentiation therapy of tumors.

The invention discloses a kit for detecting drug resistance of malignant parenchymatous tumors to chemotherapeutic drugs. The kit comprises malignant parenchymatous tumor drug-resistant cell cDNA standard samples, an SYBR Green polymerase chain reaction system, MDR1 and LIMK1 genes for amplification and housekeeping gene primer pairs. When the kit is used, cells of the malignant parenchymatous tumors of a lung cancer and the like are intermittently exposed in vincristine with increasing gradients, and a differential drug-resistant cell substrain is established. It is detected and found through a fluorescent quantitative PCR instrument that expression of the MDR1 gene is enhanced along with increasing of the drug-resistant degree, and expression of the LIMK1 gene is enhanced in cells which have low and moderate resistance to the drugs and retraced in cells which have high resistance to the drugs. Therefore, whether the malignant parenchymatous tumors are resistant to the drugs or not and the drug-resistant degree of the malignant parenchymatous tumors can be diagnosed by jointly detecting expressions of the MDR1 and LIMK1 genes; meanwhile, detection of the expressions of the MDR1 and LIMK1 genes can be used for preparing a chemotherapeutic drug resistance screening preparation, and an accurate therapeutic regimen can be provided for a patient subjected to malignant parenchymatous tumor chemotherapy.

The invention discloses an application of beta-dextran in preparation of human dendritic cell tumor vaccine. The application comprises culturing human peripheral blood mononuclear cells with culture medium containing GM-CSF (granulocyte-macrophage colony-stimulating factor) and IL-4 (interleukin-4) to obtain immature human dendritic cell; and inducing loading of tumor antigen onto the immature human dendritic cell through beta-dextran with concentration of 80-120 mug / mL, to obtain human dendritic cell tumor vaccine. According to the invention, the human dendritic cell tumor vaccine is obtained by inducing loading of tumor antigen onto the immature human dendritic cell through beta-dextran. The vaccine can improve immunizing potency of human dendritic cell, promote multiplication capacity of T-cells, especially can externally stimulate the T-cells to achieve specific tumor killing ability, thereby treating various malignant solid tumors.

The invention relates to an ultra performance liquid chromatography-tandem mass spectrometry (UPLC-MS / MS) method for determining plasma concentration of doxorubicin analogue and metabolite M3 in human plasma and provides a method for determining the concentration of doxorubicin analogue and C13 alcohol metabolite M3 in human plasma through UPLC-MS / MS. The method is carried out with formic acid water-acetonitrile as a mobile phase. The method for detecting the doxorubicin analogue and the metabolite M3 provided by the invention is high in sensitivity and good in repeatability, and can meet the requirements of quantitative analysis of clinical pharmacokinetic biological samples for treating malignant parenchymatous tumors by the doxorubicin analogue.

The invention provides a preparation method for extractive originating from an araliaceae plant, notoginseng. The extractive of the category mainly contains extractive of dammarane type, tetracyclic triterpene category, protopanaxadiol type and saponin category, wherein the content of ginsenoside Rb1 and Rd is not lower than 60 percent, and the content of ginsenoside Re, Rg1, and notoginseng saponin R1 is not higher than 5 percent. The notoginseng is extracted by using alcohol containing water as the solvent, chromatography to the extracting solution through a chromatographic column is performed to obtain elutriant, reversed phase and liquid phase gradient elution is performed, the elutriant is collected, and then the target extractive is obtained through concentration. The extraction process of the invention can effectively remove impurities of sugar, protein, amino acid, and the saponin of the protopanaxadiol type of the notoginseng, etc., and improve the content of effective components. The effective components are definite, the process is simple, the quality is controllable, and the invention is suitable for industrialized production, thereby being applied for preparing medicines treating malignant solid tumors.

This application provides the construction and application of a fourth-generation chimeric antigen receptor T (CAR-T) cell (expressing IL-7 and CCL19) targeting Nectin-4 on the surface of malignant tumors. The present invention takes the two spatial epitopes of the Nectin-4 antigen as targets, and the fourth-generation CAR-T constructed is used to treat malignant solid tumors expressing the Nectin-4 antigen, so as to solve the immune problem of CAR-T in the treatment of solid tumors escape problem; and the construction of the fourth-generation CAR-T can enhance its proliferation ability and continuous survival ability, so as to effectively treat solid tumors, and provide a new strategy for the effective prevention and treatment of solid tumor recurrence / metastasis after surgery.

The present invention provides a method for separating and inducing tumor-infiltrating T lymphocytes suitable for malignant solid tumors, specifically, including 1) processing the tumor tissue into a volume of 0.5-3mm 3 2) Matrigel is spread in the cell culture plate, and the tissue piece of the tumor tissue processed in step 1) is transferred to Matrigel for coating; 3) The coated tissue in step 2) Transfer the tissue block to another cell culture plate and incubate for 10-60 minutes; 4) add pre-amplification medium to the cell culture plate in step 3), and carry out pre-amplification culture for 10-30 days, every 2- For 3 days, half of the pre-amplification medium was used to change the medium. The invention provides an effective method for separating and inducing tumor infiltrating T lymphocytes for the specific biological treatment of malignant solid tumors. The tumor infiltrating T lymphocytes separated by the method of the invention have high purity and stronger tumor cell killing activity.

Circulating tumor cells (CTCs) are associated with metastasis of malignant solid tumors in a patient. Presented here is evidence that CTCs exhibit cell cycle phase variability and that there is a strong correlation between the number of CTCs in a mitotic cell cycle phase and the prospects for long term survival of the subject from which the cells were obtained. Also presented herein are methods of determining the mitotic cell cycle phase of CTCs from a patient having cancer and using the information in grading malignant solid tumors and predicting the likelihood of survival of the patient.